ArticleScientific reports2026
Hematological ratios in pediatric patients with alopecia areata based on a nationwide retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our goal was to analyze hematological ratios in patients with pediatric alopecia areata (AA) and assess their potential as markers of disease exacerbation. A retrospective cohort study of 31,869 patients (aged 0–18) with AA was conducted using blood samples collected within 30 days of diagnosis and 12–18 months prior. Univariate and multivariable analyses were used to compare the hematological ratios among healthy controls, patients with mild AA, and patients with severe AA. Data were gathered from Israel’s Clalit database and Soroka Hospital, Beer Sheva, and represented both Arab and Jewish populations. The eosinophil/lymphocyte ratio (ELR), eosinophil/monocyte ratio (EMR), and eosinophil/neutrophil ratio (ENR) were elevated in patients with AA (0.11 vs. 0.10, p < 0.001; 0.75 vs. 0.57, p < 0.001; 0.12 vs. 0.10, p < 0.001, respectively). Elevated ELR increased the likelihood of AA by 3.31 times (95% CI: 2.20–5.01) and ENR by 2.61 times (95% CI: 1.86–3.69). Severe patients presented increases in the ELR (0.11 vs. 0.10, p < 0.01), ENR (0.10 vs. 0.09, p < 0.001), and EMR (0.70 vs. 0.63, p < 0.001). Elevated ENR was observed in severe patients 12–18 months prior to diagnosis. Eosinophilic ratios could serve as promising markers to study pathophysiology and potentially predict exacerbations of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.